INOVIQ signs validation deal with Sonic Healthcare USA

INOVIQ (ASX: IIQ): Sonic validation deal sets 2028 target for ovarian cancer test. INOVIQ (ASX: IIQ), a Melbourne biotech developing exosome-based diagnostics and cancer therapeutics, has signed a Validation and License Option Agreement with Sonic Healthcare USA. It gives the company's ovarian cancer blood test a route into America's laboratory testing market, although the path ahead is conditional. INOVIQ has granted Sonic Healthcare USA a licence to transfer, optimise and validate its EXO-OC test at a laboratory in Rye Brook, New York. Sonic has not committed to a commercial licence, and the financial terms are confidential. What the Agreement covers. * A licence for Sonic to transfer, optimise and validate EXO-OC at its own certified laboratory * A non-exclusive option for Sonic to pursue a later licence to offer the test as a Laboratory Developed Test (LDT) in the United States * No commitment from Sonic to a commercial licence, broader technology transfer or partnership Any future arrangement depends on successful validation, Sonic exercising the option and further commercial talks. Why Sonic Healthcare USA matters. Sonic Healthcare USA belongs to one of the world's leading healthcare groups and delivers pathology services to 20 million physicians and patients across the country. Its Rye Brook site is CAP/CLIA-certified and specialises in advanced molecular diagnostics. Sonic's chief medical officer, Dr Mohamed Salama, was careful with his wording. He described the current role as validation only, with any clinical use or commercial deal considered once that work is complete. For a small-cap diagnostics developer, that kind of cautious endorsement still carries weight, because it puts the test in front of a major US operator. How EXO-OC works. EXO-OC is a blood test designed to detect ovarian cancer early in women who show no symptoms. It uses IIQ's EXO-NET technology to isolate exosomes, then combines several exosomal miRNA biomarkers with the established CA125 marker in a machine-learning algorithm. An updated algorithm delivered 92.3 per cent sensitivity for stage I/II cancers and 92.5 per cent across all stages, at 98 per cent specificity, in a retrospective case-control study. Those results support an initial focus on women at elevated risk. Sonic has not yet independently validated them, so they should not be read as its endorsement. For a closer look at the stock's recent trading and valuation, its latest analysis of INOVIQ (ASX: IIQ) is available here. What comes next. The company expects optimisation and validation to take 12 to 18 months, pointing to early calendar 2028 for a potential LDT launch. In parallel, it plans to collect clinical samples with US ovarian cancer specialists and hospitals to support clinical validation, regulatory and reimbursement work. Progress will depend partly on how quickly samples become available. The strategy has two stages. An LDT comes first because it offers a quicker route to patients and revenue. IIQ then hopes to develop EXO-OC as an In Vitro Diagnostic for broader screening, which would widen its reach and reimbursement options. The market opportunity. Ovarian cancer is often caught late, when survival rates are poor, which is why early detection is seen as the biggest opening for better outcomes. Grand View Research expects the global ovarian cancer diagnostics market to reach US$3.1 billion by 2035. That is the prize IIQ is chasing, though a validated product is still some way off. IIQ also lodged an Appendix 3X on 2 November 2026 for Andrew Chapman, who joined its board that day. The notice lists about 9.1 million shares in which he holds a relevant interest through Merchant Opportunities Fund, Merchant Group Pty Ltd and Merchant Funds Management. It also shows a smaller parcel held through three family-linked accounts. The filing signals a significant shareholder presence at board level just as the company moves into its validation phase. Share price reaction. IIQ shares traded higher on announcement day but remain near the bottom of a 52-week range running from 13 cents to 56.5 cents. That leaves the stock well below its yearly peak. For investors, the question is whether Sonic's validation work can turn promising study data into something the market can price with more confidence.